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Ether lipids and their derivatives represent a new class of
compounds for experimental therapy of neoplasia. The
activity of these agents is partially mediated through non-
specific host resistance cells (Munder et al., 1977). In addi-
tion, they possess direct effects on neoplastic cells. They are
cytotoxic, anti-invasive and can induce cell differentiation.
Although the molecular mechanisms leading to these direct
effects are yet poorly understood, accumulation of these
agents in neoplastic cells, disturbing lipid metabolism and
subsequently destroying cell membranes seems to be crucial
for their cytotoxicity. Thus, in the process of developing
these new drugs cell membranes have evolved as a target for
experimental cancer therapy. Some reviews on the develop-
ment in this area have been published during the last years
(Berdel et al., 1985, 1987; Baumann et al., 1987). This is a
brief update of significant new aspects, which could be fur-
ther exploited experimentally or are important for the clinical
development of these drugs.
Precfinical studies
Alkyl-lysophospholipids (ALP) are analogs of lysophosphati-
dylcholine and were originally synthesised as a new class of
biological response modifiers (Munder et al., 1977). During
an investigation of the influence of ALP analogs on cellular
immunity, strong antitumour effects of some of these com-
pounds were observed in the allogeneic Ehrlich ascites
tumour in mice (Munder et al., 1977). Further studies
showed antimetastatic activity in the anaplastic Lewis lung
carcinoma in mice (Berdel et al., 1980). Additional thera-
peutic screening of the first generation ALP analogs in
different laboratories subsequently revealed that a wide vari-
ety of murine and rat tumour and leukaemia models is
sensitive to the therapeutic activity of these lipids with some
other tumour and leukaemia systems being rather resistant to
this material (see Berdel, 1990). Some of the compounds,
such as the ALP analog ET-18-OCH3 or the thioether-
phospholipid BM 41.440 (see Figure 1) have been also tested
for therapeutic activity in xenotransplanted human tumours
growing in athymic (nu/nu) mice. Considerable growth re-
tardation of some gynecological tumours was found under
systemic therapy with some of these compounds (Runge et
al., 1980). However, other xenotransplanted human tumours
have been found as being resistant (Leder et al., 1987).
Vogler and co-authors (Glasser et al., 1984; Vogler et al.,
1987) demonstrated selective cytotoxic activity of ET-18-
OCH3 in experiments with a mouse model for syngeneic bone
marrow transplantation. Lethally irradiated mice were trans-
planted with normal bone marrow cells containing 1-2%
leukaemic cells (WEHI-3B) to simulate a remission marrow
after the cells were incubated with various concentrations of
ET-18-OCH3 in vitro. All of the mice given cells not treated
with ET-18-OCH3 in vitro succumbed to leukaemia, whereas
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Figure 1 Structures of ET-18-OCH3 a, BM 41.440, b, SRI 62-
834, c, Hexadecylphosphocholine, d, and ara-CDP-DL-PTBA e.
there was a dose-related increase in survival in those animals
transplanted with ET-18-OCH3-treated cells. Thus, ether
lipids seem to be suited for purging residual malignant cells
from marrows prior to autologous bone marrow transplant-
ation (ABMT).
During the early treatment studies, it became evident that
the antineoplastic activity of some ALP analogs in vivo might
be partially mediated by cytotoxic macrophages (Munder et
al., 1977; Berdel et al., 1980; Andreesen et al., 1984). Assess-
ing the importance of cytotoxic macrophages as mediators of
ALP-effects, it could be shown that macrophages not only
are cytotoxic in vitro to a variety of neoplastic cells after
incubation with these lipids, but can be also used for success-
ful treatment of syngeneic tumour and metastasis develop-
d
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ment in vivo. Putative involvement of other cell types of
cellular host resistance has been discussed controversely
(Andreesen et al., 1979; Berdel et al., 1985; Talmadge et al.,
1987).
Later, some direct effects of these drugs on tumour cells
were observed. The most striking observation was that ALP
with an ether linkage in the sn-I position of the glycerol
moiety and a metabolically stable substitution in the sn-2
position were directly antiproliferative and cytotoxic in vitro
at micromolar concentrations towards cells of various types
of leukaemia and a wide variety of lymphomas and solid
tumours, when co-incubated with neoplastic cells for more
than 24 h. However, sn-I ester analogs were ineffective within
this dose range, regardless of changes made in the sn-2
position ofthe molecule (Andreesen et al., 1978; Berdel et al.,
1985). Scanning electron microscopy revealed that destruc-
tion of the outer cell membrane occurs during incubation
with the lipids (Berdel et al., 1983; Noseda et al., 1989). For
the purging approach in the setting of ABMT it might be of
interest that cell lines selected for resistance towards different
cytotoxic drugs do not develop major cross-resistance to the
cytotoxicity of ether lipids (Himmelmann et al., 1990). Fur-
thermore, several laboratories have clearly demonstrated
preferential cytotoxicity ofALP analogs within a certain dose
range against leukaemic blasts, in comparison with normal
human hematopoietic precursor cells in various assay systems
in vitro (Andreesen et al., 1978; Dulisch et al., 1985; Schick et
al., 1987; Okamoto et al., 1987a and b; Verdonck et al.,
1990).
The molecular mechanisms within the cytotoxic actions of
these ether lipids are poorly understood and are still contro-
versial, although a multitude of experimental studies have
been performed addressing this question. However, there is
agreement that cellular uptake and accumulation of these
compounds are crucial early steps in a cascade of events
leading to cell death (Hoffman et al., 1986). Bazill and Dexter
(1990) have concluded from their recent studies that one of
the principal determinants of sensitivity or resistance to the
cytotoxic action ofether lipids may be the rate at which cells
take them up by endocytosis. Several studies dealing with the
accumulation, intracellular fate and metabolism of ether
lipids in neoplastic cells, have shown that these compounds
are topically and metabolically stable and are only slowly
degraded it at all, for example by phospholipase C (Snyder et
al., 1987). Preexisting endogenous ether lipid concentrations
in the membranes of the target cells seem to play an import-
ant role in ether lipid cytotoxicity (Chabot et al., 1989) and
cellular cholesterol can down-modulate their cytotoxicity
(Diomede et al., 1990). Kosano et al. (1988, 1989) have
reported reduction of epidermal growth factor (EGF)-binding
in human breast cancer cell lines by ether lipids and its
correlation with cytotoxicity, as well as inhibition of EGF
receptor-uptake. Additionally, there is inhibition of estradiol
uptake and transforming growth factor a secretion in a
human breast cancer cell line (Kosano et al. 1990) as well as
inhibition of the binding of granulocyte-macrophage colony-
stimulating factor on human leukaemic cells by an ether lipid
(Shoji et al., 1990). Seewald et al. (1990) described inhibition
of growth factor-dependent inositol phosphate Ca2" signall-
ing by ether lipids. In contrast to these findings, transferrin
binding can be induced by some ALP (Kosano & Takatani
1990). Further studies have shown inhibition of protein
kinase C activity and related transmembrane signalling, as
well as elevation of leukaemic cell intracellular calcium not
being due to an early and grossly disruptive effect of the drug
on the membrane structure (Helfman et al., 1983; Shoji et al.,
1988; Lazenby et al., 1990). Disturbance of phosphocholine
biosynthesis has been reported in addition (Vogler et al.,
1985; Hermann & Neumann, 1986). However, whether these
effects share responsibility for the cytotoxic action of ether
lipids remains to be further established.
There is good experimental evidence that ether lipids show
a variety ofdirect effects on neoplastic cells, even when tested
at sublethal dose levels. Honma and co-workers (1981) have
studied the morphological and functional induction of
differentiation in leukaemic cells by various of these struc-
tures. Furthermore, in an attempt to understand the anti-
metastatic effect of ether lipids in vivo, studies done by
Storme et al. (1985) showed anti-invasive activity of ET-18-
OCH3 and BM 41.440 in an in vitro model, in which malig-
nant MO4 cells were confronted with precultured fragments
ofembryonic chick cardiac muscle or lung fragments. Chang-
ings of cell membrane fluidity (Storme et al., 1985) as well as
modification of cell surface carbohydrates (Bolscher et al.,
1988) were discussed as playing a role in this anti-invasive
effect of the ether lipids tested.
Development of new ether lipids
With the first generation of ALP analogs and particularly
ET-18-OCH3 as a reference structure, many laboratories have
embarked on the chemical synthesis and the screening of a
variety of structurally related compounds with possible
antineoplastic activity (for further literature see Berdel, 1990).
Among structures showing promising in vitro and/or in vivo
action are 1-thioether phospholipids, such as BM 41.440,
other sulfur-analogs, alkyl-ethylene-glycophospholipids, 2-
acetamide analogs of ALP, 2-alkoxyalkyl- and 2-
alkoxyalkenyl-phosphocholines, l-N-alkylamide analogs of
glycerophosphocholine and various non-phosphorus ether
lipids. Other structures, such as analogs of platelet activating
factor and alkyl-linked lipoidal amines show in vitro
antitumour properties. However, some of them, such as the
lipoidal amine CP 46,665, have almost no therapeutic range
in vivo and thus are not further studied.
Addition of other cytotoxic drugs and other treatment
modalities like hyperthermia have been shown to potentiate
the cytotoxicity of some ether lipids in vitro (Okamoto et al.,
1988; Noseda et al., 1988; Fujiwara et al., 1989; Hofmann et
al., 1989). These additive or supra-additive effects are cur-
rently under further investigation. Interestingly, some of
these membrane-active ether lipid structures inhibit infectious
HIV-1 production and induce defective virus formation in
T-cells (Kucera et al., 1990). This effect is currently under
study for combination chemotherapy with DNA-interactive
anti-HIV nucleoside analogs.
Based on the hypothesis that degradation of certain ALP
analogs by a phospholipase C is required for the generation
of toxic metabolites (Fleer et al., 1987), Eibl and co-workers
have synthesised derivatives of ether lipids such as a series of
alkylphosphocholines (APC). One of the most active APC is
hexadecylphosphocholine (D 18506, Asta-Werke, Germany),
which is depicted in Figure 1. The investigators showed
impressive therapeutic in vivo activity of D 18506 in a breast
cancer model in rats (Hilgard et al., 1988). Our recent work
has concentrated on chemical conjugates of ether lipids and
other cytotoxic drugs, such as nucleoside analogs. It could be
shown, that sn-3 lipid conjugates of arabinoside-cytosine
(ara-C), when tested in vivo in various leukaemia and solid
tumour models in mice including xenografts, have a com-
paratively high therapeutic activity (Berdel et al., 1988, 1989;
Hermann & Berdel, 1989).
Clinical studies
Currently, there are four membrane-toxic lipids in early
clinical trials for treatment of cancer and leukaemia. ET-18-
OCH3, the first ether lipid entered into early clinical trials
(Berdel et al., 1985), was given to patients with non-small cell
lung cancer (NSCLC) per os in a multi-institutional phase II
drug efficacy study (Khanavkar et al., 1989). A multi-
institutional phase I drug safety trial with BM 41.440 given
orally has been recently completed (Herrmann et al., 1989)
and this drug has entered phase II drug efficacy trials in a
wide spectrum of neoplastic diseases. Hexadecylphospho-
choline is currently being studied in a phase II trial for the
topical treatment of skin metastases in patients with breast
cancer (Unger et al., 1988) and has completed two phase I210 W.E. BERDEL
trials in an oral formulation (Unger et al., 1990; Danhauser-
Riedl et al., 1990). These early clinical studies have shown
tumour responses in a small number of patients treated.
Thus, further clinical testing of these investigational drugs as
well as of other lipids on a larger scale is indicated. A cyclic
analog of ET-18-OCH3, SRI 62-834 (Sandoz Research Insti-
tute), has recently entered phase I through the CRC in the
UK.
In comparison with the concentrations of these drugs
needed for in vitro cytotoxicity the plasma levels reached for
the lipids tested in various oral formulations were rather low
(Khanavkar et al., 1989; Herrmann et al., 1989; Schaefer &
Rodewald, 1989; Unger et al., 1990; Danhauser-Riedl et al.,
1990). Limiting toxicity occurred at low doses in the gastro-
intestinal tract. Furthermore, in the NSCLC phase II study
only few remissions have been observed with some other
patients remaining with no change of their disease para-
meters for various times (Khanavkar et al., 1989). Thus, the
systemic clinical activity of these drugs as available and as
given up to now is marginal and their clinical potential
remains doubtful. On the other hand intravenous dose re-
sponse relations of some ether lipids in vivo are impressive in
animal models (Berger & Schmahl, 1987; Herrmann & Bicker,
1988). Hence, better galenic formulation and early clinical
trials with parenteral high dose/long time application of some
of these drugs is urgently warranted in order to clarify
whether the lipids available so far can be exploited as
therapeutic agents in clinical oncology.
A clinical phase I/II study to assess the safety and efficacy
of bone marrow autotransplantation after supralethal
chemotherapy and radiotherapy in patients with acute
leukaemia using remission marrows purged with ether lipids
in vitro is currently underway (Berdel et al., 1990).
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